240 related articles for article (PubMed ID: 21320541)
21. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection.
Holzer GW; Coulibaly S; Aichinger G; Savidis-Dacho H; Mayrhofer J; Brunner S; Schmid K; Kistner O; Aaskov JG; Falkner FG; Ehrlich H; Barrett PN; Kreil TR
Vaccine; 2011 May; 29(24):4132-41. PubMed ID: 21477673
[TBL] [Abstract][Full Text] [Related]
23. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
[TBL] [Abstract][Full Text] [Related]
24. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
[TBL] [Abstract][Full Text] [Related]
25. Chikungunya virus and prospects for a vaccine.
Weaver SC; Osorio JE; Livengood JA; Chen R; Stinchcomb DT
Expert Rev Vaccines; 2012 Sep; 11(9):1087-101. PubMed ID: 23151166
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
[TBL] [Abstract][Full Text] [Related]
27. Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm.
Rudd PA; Raphael AP; Yamada M; Nufer KL; Gardner J; Le TT; Prow NA; Dang N; Schroder WA; Prow TW; Suhrbier A
Vaccine; 2015 Sep; 33(39):5172-80. PubMed ID: 26296498
[TBL] [Abstract][Full Text] [Related]
28. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses.
Prow NA; Liu L; Nakayama E; Cooper TH; Yan K; Eldi P; Hazlewood JE; Tang B; Le TT; Setoh YX; Khromykh AA; Hobson-Peters J; Diener KR; Howley PM; Hayball JD; Suhrbier A
Nat Commun; 2018 Mar; 9(1):1230. PubMed ID: 29581442
[TBL] [Abstract][Full Text] [Related]
29. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
[TBL] [Abstract][Full Text] [Related]
30. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
[TBL] [Abstract][Full Text] [Related]
31. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.
Sun Y; Li HY; Tian DY; Han QY; Zhang X; Li N; Qiu HJ
Vaccine; 2011 Oct; 29(46):8364-72. PubMed ID: 21888938
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
[TBL] [Abstract][Full Text] [Related]
33. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.
Plante K; Wang E; Partidos CD; Weger J; Gorchakov R; Tsetsarkin K; Borland EM; Powers AM; Seymour R; Stinchcomb DT; Osorio JE; Frolov I; Weaver SC
PLoS Pathog; 2011 Jul; 7(7):e1002142. PubMed ID: 21829348
[TBL] [Abstract][Full Text] [Related]
34. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
[TBL] [Abstract][Full Text] [Related]
35. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
36. Serological correlates of immune protection conferred by Chikungunya virus infection.
Sheela PJ; Sumathy K
Acta Virol; 2013; 57(4):471-3. PubMed ID: 24294963
[TBL] [Abstract][Full Text] [Related]
37. Deinococcus Mn
Gayen M; Gupta P; Morazzani EM; Gaidamakova EK; Knollmann-Ritschel B; Daly MJ; Glass PJ; Maheshwari RK
Vaccine; 2017 Jun; 35(29):3672-3681. PubMed ID: 28576570
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model.
Goh LY; Hobson-Peters J; Prow NA; Gardner J; Bielefeldt-Ohmann H; Pyke AT; Suhrbier A; Hall RA
Clin Immunol; 2013 Dec; 149(3):487-97. PubMed ID: 24239837
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
